Relative contributions of BRCA1 and BRCA2 mutations to "triple- negative" breast cancer in Ashkenazi Women

Breast Cancer Research and Treatment

Volumn 129, Issue 1, 2011, Pages 185-190

  Comen, E ^a   Davids, M ^b,c   Kirchhoff, T ^a   Hudis, C ^a,b   Offit, K ^a,b   Robson, M ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Ashkenazi; BRCA1; BRCA2; Triple negative breast cancer

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; ASHKENAZI JEWISH; BRCA2 GENE; CONTROLLED STUDY; ETHNIC GROUP; FAMILY HISTORY; FEMALE; GENE MUTATION; GENOTYPE; HETEROZYGOTE; HUMAN; ONCOGENE; OVARY CANCER; PHENOTYPE; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; FOUNDER EFFECT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; JEWS; MIDDLE AGED; MUTATION; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 79960834725     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1433-2     Document Type: Article

References (24)

1. CM Perou SS Jeffrey M van de Rijn CA Rees MB Eisen DT Ross A Pergamenschikov CF Williams SX Zhu JC Lee D Lashkari D Shalon PO Brown D Botstein 1999 Distinctive gene expression patterns in human mammary epithelial cells and breast cancers Proc Natl Acad Sci USA 96 16 9212 9217 10430922 10.1073/pnas.96.16.9212 1:CAS:528:DyaK1MXltVequro%3D (Pubitemid 29374734)
2. EA Rakha JS Reis-Filho IO Ellis 2008 Basal-like breast cancer: a critical review J Clin Oncol 26 15 2568 2581 10.1200/JCO.2007.13.1748 18487574 10.1200/JCO.2007.13.1748
3. NC Turner JS Reis-Filho 2006 Basal-like breast cancer and the BRCA1 phenotype Oncogene 25 43 5846 5853 10.1038/sj.onc.1209876 16998499 10.1038/sj.onc.1209876 1:CAS:528:DC%2BD28XhtVSgurjO (Pubitemid 44453440)
4. N Turner A Tutt A Ashworth 2004 Hallmarks of 'BRCAness' in sporadic cancers Nat Rev Cancer 4 10 814 819 10.1038/nrc1457 15510162 10.1038/nrc1457 1:CAS:528:DC%2BD2cXos1ymu7g%3D (Pubitemid 39331153)
5. DG Evans F Lalloo A Cramer EA Jones F Knox E Amir A Howell 2009 Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing J Med Genet 46 12 811 817 10.1136/jmg.2009.067850 19542080 10.1136/jmg.2009.067850 1:STN:280:DC%2BD1MjptlWlug%3D%3D
6. JP Struewing P Hartge S Wacholder SM Baker M Berlin M McAdams MM Timmerman LC Brody MA Tucker 1997 The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews N Engl J Med 336 20 1401 1408 10.1056/NEJM199705153362001 9145676 10.1056/NEJM199705153362001 1:STN:280:DyaK2s3nsVShug%3D%3D (Pubitemid 27208598)
7. ME Robson PO Chappuis J Satagopan N Wong J Boyd JR Goffin C Hudis D Roberge L Norton LR Begin K Offit WD Foulkes 2004 A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment Breast Cancer Res 6 1 R8 R17 10.1186/bcr658 14680495 10.1186/bcr658 1:CAS:528:DC%2BD2cXnsl2hsw%3D%3D
8. L Zhang T Kirchhoff CJ Yee K Offit 2009 A rapid and reliable test for BRCA1 and BRCA2 founder mutation analysis in paraffin tissue using pyrosequencing J Mol Diagn 11 3 176 181 10.2353/jmoldx.2009.080137 19324993 10.2353/jmoldx.2009.080137 1:CAS:528:DC%2BD1MXmtVOksLw%3D
9. RG Newcombe 1998 Two-sided confidence intervals for the single proportion: comparison of seven methods Stat Med 17 8 857 872 9595616 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E 1:STN:280:DyaK1c3lsl2rsg%3D%3D (Pubitemid 28185165)
10. EB Wilson 1927 Probable inference, the law of succession, and statistical inference J Am Stat Assoc 22 158 209 212 10.2307/2276774
11. JS Kwon AM Gutierrez-Barrera D Young CC Sun MS Daniels KH Lu B Arun 2010 Expanding the criteria for BRCA mutation testing in breast cancer survivors J Clin Oncol 28 27 4214 4220 10.1200/JCO.2010.28.0719 20733129 10.1200/JCO.2010.28.0719
12. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton J, Potter J, Lanchbury JS, Stemke-Hale KA, Hennessy B, Arun BK, Hortobagyi GN, Do K-A, Mills GB, Meric-Bernstam F (2011) Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clinical Cancer Research. doi: 10.1158/1078-0432.ccr-10-2560
13. WD Foulkes IM Stefansson PO Chappuis LR Begin JR Goffin N Wong M Trudel LA Akslen 2003 Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer J Natl Cancer Inst 95 19 1482 1485 14519755 1:CAS:528: DC%2BD3sXnvVCjtrk%3D (Pubitemid 37279334)
14. SE Karp PN Tonin LR Bégin JJ Martinez JC Zhang MN Pollak WD Foulkes 1997 Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women Cancer 80 3 435 441 9241077 10.1002/(SICI)1097-0142(19970801)80:3<435::AID-CNCR11>3.0.CO;2-Y 1:STN:280:DyaK2szotlSrtA%3D%3D (Pubitemid 27323413)
15. ME Hammond DF Hayes AC Wolff PB Mangu S Temin 2010 American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer J Oncol Pract 6 4 195 197 10.1200/JOP.777003 21037871 10.1200/JOP.777003
16. DP Atchley CT Albarracin A Lopez V Valero CI Amos AM Gonzalez-Angulo GN Hortobagyi BK Arun 2008 Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer J Clin Oncol 26 26 4282 4288 10.1200/JCO.2008.16.6231 18779615 10.1200/JCO.2008.16.6231
17. Kandel MJ, Stadler Z, Masciari S et al. (2006) Prevalence of BRCA1 mutations in triple negative breast cancer (BC). J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I, vol 24, No. 18S (June 20 Supplement)
18. T Distelman-Menachem T Shapira Y Laitman B Kaufman F Barak S Tavtigian E Friedman 2009 Analysis of BRCA1/BRCA2 genes' contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women Fam Cancer 8 2 127 133 10.1007/s10689-008-9216-6 18798010 10.1007/s10689-008-9216-6 1:CAS:528:DC%2BD1MXlvV2jtrY%3D
19. Y Laitman RT Borsthein D Stoppa-Lyonnet E Dagan L Castera M Goislard R Gershoni-Baruch H Goldberg B Kaufman N Ben-Baruch J Zidan T Maray L Soussan-Gutman E Friedman 2010 Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel Breast Cancer Res Treat 10.1007/s10549-010-1217-0
20. ND Kauff P Perez-Segura ME Robson L Scheuer B Siegel A Schluger B Rapaport TS Frank K Nafa NA Ellis G Parmigiani K Offit 2002 Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families J Med Genet 39 8 611 614 12161607 10.1136/jmg.39.8.611 1:CAS:528:DC%2BD38XntFSkur0%3D (Pubitemid 34864569)
21. J Chang SG Hilsenbeck JH Sng J Wong GC Ragu 2001 Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients Clin Cancer Res 7 6 1739 1742 11410514 1:CAS:528:DC%2BD3MXltV2hs7Y%3D (Pubitemid 32708643)
22. R Lidereau F Eisinger MH Champeme C Nogues I Bieche D Birnbaum C Pallud J Jacquemier H Sobol 2000 Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer Cancer Res 60 5 1206 1210 10728676 1:CAS:528:DC%2BD3cXhvFWrsbs%3D (Pubitemid 30151984)
23. BG Haffty DH Choi S Goyal A Silber K Ranieri E Matloff MH Lee M Nissenblatt D Toppmeyer MS Moran 2009 Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups Ann Oncol 20 10 1653 1659 10.1093/annonc/mdp051 19491284 10.1093/annonc/mdp051 1:STN:280:DC%2BD1MnjvFOhtw%3D%3D
24. SR Young RT Pilarski T Donenberg C Shapiro LS Hammond J Miller KA Brooks S Cohen B Tenenholz D Desai I Zandvakili R Royer S Li SA Narod 2009 The prevalence of BRCA1 mutations among young women with triple-negative breast cancer BMC Cancer 9 86 10.1186/1471-2407-9-86 19298662 10.1186/1471-2407-9-86 1:CAS:528:DC%2BD1MXjvVSitLg%3D